Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.
KIRhub 2.0· v2Sign in
← Cases

BRAF

RBC: BRAF · Substrate: MEK1 (K97R) ·

Top inhibitors

MeasuredDerived
DrugInhibition %Gini
Ripretinib100.00.67
Ponatinib99.40.53
Sorafenib98.50.78
Dabrafenib98.30.63
Regorafenib98.30.72
Encorafenib98.00.76
Apatinib94.10.70
Vemurafenib92.80.60
Nilotinib85.80.77
Dasatinib80.60.70
Pazopanib79.30.67
Umbralisib65.30.67
Pacritinib58.50.45
Gedatolisib56.50.61
Erdafitinib54.10.74

Known variants

Cancer associations

MutationCancer typeOrganSource
D485Gcarcinoma_lungLunghttps://doi.org/10.1158/2159-8290.CD-12-0095
D485GColon/Colorectal CancerLarge Intestinehttps://doi.org/10.1093/nar/gkaa945
P490Ycarcinoma_lungLunghttps://doi.org/10.1158/2159-8290.CD-12-0095
P490YColon/Colorectal CancerLarge Intestinehttps://pubmed.ncbi.nlm.nih.gov/15126572/
R506Kcarcinoma_lungLunghttps://www.cancer.gov/tcga.
R506KColon/Colorectal CancerLarge Intestinehttps://www.cancer.gov/tcga.
V599Emalignant_melanoma_skinSkinhttps://pubmed.ncbi.nlm.nih.gov/15126572/
V599Ecarcinoma_thyroidThyroidhttps://pubmed.ncbi.nlm.nih.gov/15126572/
V599EColon/Colorectal CancerLarge Intestinehttps://doi.org/10.1158/2159-8290.CD-12-0095
G464VBreast CancerBreasthttps://doi.org/10.1093/nar/gkaa945
G464Vcarcinoma_breastBreasthttps://doi.org/10.1093/nar/gkaa945
G464Vcarcinoma_lungLunghttps://doi.org/10.1093/nar/gkaa945
G464Vlymphoid_neoplasm_haematopoietic_and_lymphoid_tissueBlood/Lymphatic Systemhttps://doi.org/10.1093/nar/gkaa945
G464Vcarcinoma_biliary_tractBiliary Tracthttps://doi.org/10.1093/nar/gkaa945
G464Vcarcinoma_large_intestineLarge Intestinehttps://doi.org/10.1093/nar/gkaa945
G464Vcarcinoma_ovaryOvaryhttps://doi.org/10.1093/nar/gkaa945
G464VBTCA-SGBiliary Tracthttps://doi.org/10.1093/nar/gkaa945
G464VLUAD-USLunghttps://doi.org/10.1093/nar/gkaa945
G464VLUSC-USLunghttps://doi.org/10.1093/nar/gkaa945
G464VLUADLunghttps://doi.org/10.1093/nar/gkaa945
Open in new tab